[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"basedow-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:basedow-disease":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100602013","describe-the-progression-of-inflammatory-orbitopathy-and-the-biological-progression-of-patients-receiving-second-line-treatment-100602013",false,"NCT07117981","Describe the Progression of Inflammatory Orbitopathy and the Biological Progression of Patients Receiving Second-line Treatment","Treatment of Graves' Orbitopathy in Patients Failing Corticosteroid Therapy: Multicenter National Retrospective Study- Basedow","HZN-IIT","Inclusion Criteria:\n\n* Patients aged 18 and older with moderate to severe orbitopathy;\n* Patients followed in endocrinology with the goal of achieving euthyroidism;\n* Corticosteroid-resistant patients: patients who have received at least 3 weeks of treatment with 500 mg weekly corticosteroid boluses and have not shown improvement in the clinical activity score (CAS);\n* Corticosteroid-dependent patients: relapse with a CAS of 3 or higher when decreasing or stopping corticosteroid therapy;\n* Patients with a CAS ≥ 3 or CAS \\\u003C3 with moderate to severe orbitopathy (according to EUGOGO);\n* Patients treated with immunotherapy, biotherapy, or radiotherapy as second-line treatment;\n* Patients who are not opposed to the reuse of their health data.\n\nExclusion Criteria:\n\n* Patients who have undergone bone or fat decompression surgery;\n* Patients with severe corneal involvement (Grade B or C; NO SPECS classification);\n* Patients with optic neuropathy (Grade B and C; NO SPECS classification);\n* Patients who have received 1 gram corticosteroid boluses for dysthyroid orbitopathy;\n* Patients who have opposed the reuse of their health data.","ALL","18 Years",{"count":20,"type":21},100,"ESTIMATED","OBSERVATIONAL","Describe the progression of inflammatory orbitopathy and the biological progression of patients receiving second-line treatment (immunosuppressants, radiotherapy, or biotherapy).",[25],"Basedow Disease","RECRUITING","2025-08-12",{"date":29,"type":30},"2025-08-15","ACTUAL",{"date":32,"type":30},"2024-11-01",{"date":34,"type":21},"2025-12",{"name":36,"class":37},"Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts","OTHER",9]